Member Info for DonaldTrumpsWig

He can't be concise because he's thick. He comes on here to hang around smart people hoping some of it will rub off but sadly, you can't polish a turd.

Sorry if I've missed it Ice, but do we know how many STS patients are being dosed in C7? Guessing they are at MSK under Dr Tap?

Actually they didn't Mat, both Tap and Banerji were very circumspect in relation to making any direct references to AVCT/AVA 6k trial, unless I missed something. Twelves was more direct in his references, however he did this as a member of the audience as opposed to being an 'official' speaker.

Total garbage. How can you possibly write an article about the financial prospects of Avacta without a single mention of the very thing that is driving the SP growth.

Where do they find these clowns?

I have no problem with any posters and have never filtered anyone. If you are incapable of recognising a posters intentions for what they are then that is on you in my opinion.

I am a fan of Myles and RAH et al because they always caveat their opinions with their reasoning. Whether I or anyone else agree with those opinions is moot but accusing them of constantly ramping is unfair particularly when much of what they say is backed often supported by sound scientific reasoning.

Talking of long lost posters, where is Arnold Palmer/Poundcake/Moneysponge when the SP is up a few pennies?

Apologies in advance for that NY.

The point I didn't actually make in my last post was that in light of their previous experience, Dr Smith and AVCT could be forgiven for wanting to avoid anything to do with the Tories and UK bureaucracy and take Pre/Cision to the States.

i think the current covid enquiry is shedding light on the absolute shambles johnson/han****/sunak presided over back in 2020/21. to think we genuinely believed that there was some process regarding our lft and the mhra/porton down etc??. it makes me shudder to think how much of my own money i invested in avct at the time on the back of that 'opportunity' underwritten by guff from johnson claiming to be committed to supporting the uk diagnostic industry !! what garbage.

contrary to anything wyn might say about the integrity of dr smith at the time, how could avct possibly hope to navigate the nonsense that was occurring in no10. talk about trying to nail blancmange to the ceiling?

i can only say thank god for ava/pre/cision and the therapeutics division and that we weren't left high and dry like mologic/abingdon/gad etc etc

When we have the Avacta $200 party, Mr Size Buyer is definitely buying the drinks Hurstbot, he must have millions of shares already.

Just to add to RMFat's excellent post. I would consider myself one of the long established accounts that have been here for years.

In that time we have seen many 'pivotal' RNS's that have delivered everything we have hoped & expected in terms of the science yet have failed to move the SP, which today sits at a price which is very close to its 3 year average.

We have been on a journey from the LFT 'clinical validation' RNS in April 2021, supported by the infamous post from 'Unprecedented' convincing us that we were the sovereign test and about to win the a chunk of the £975 million DHSC contract, right up to today and the latest C6/7 update..

Each time we have believed that the next RNS will be the one that delivers the mystical re-rate we have had to move our horizon forward onto the next major update, and here we are again pinning our expectations on the Q4 update.

My point: There will be no major surprises in the Q4 update because we know most of what it will reveal already. We know that the safety and tolerability is confirmed and I have yet to read a sensible explanation that counters the theory that if you hit cancer cells with up to 3.5 times more doxorubicin than normal, then more of them will die.

Those irrefutable facts are already confirmed via RNS and the only data we are awaiting is to what extent the benefits of Pre/Cision and AVA6k can be expanded to a wider patient population.

Will the Q4 update shift the SP?, from experience, probably not, but we must remember that a jump to £2.50 or £3.50 etc is not the end game here.

When we learn just how revolutionary this paradigm shift is then it will be almost inevitable that BP will covet the technology and this is when us bitter old LTH's will get our payday.

Hold tight and enjoy the weekend everyone.

'The good news is size buyers will have to pay 145+ any minute'.

Nahhh if they wait until the P1a Ribena scam is revealed they will get them for 70p or maybe 40p or maybe for free

I actually think that WYNs charts have more credibility than most brokers. They provide nothing more than under researched opinions masked under a cloak of credibility provided by the company they work for.

As we have seen time and time again these brokers aren't even close to understanding the science at AVCT and as a consequence their opinions are about as accurate as their valuations (i.e. rubbish).

Hurstbot, it can't be bargained with, it can't be reasoned with, it doesn't feel pity or remorse or fear, and it absolutely will not stop… EVER, until we reach £200 ex Chinah

I was determined not to get drawn into the futility of this pointless debate and the utter nonsense spouted by Eggy/Ndn to serve no other purpose than to fuel his psychopathic desire for attention.

However it did highlight that it is worth reminding ourselves that the beauty of Pre/Cision is that we don't need to concern ourselves particularly regarding secondary effects of the AVA programme simply because, typically, the drugs being delivered are old and thoroughly tried and tested, often over many years.

Any problems whether with arthritis, or your liver or even hemorrhoids will have been thoroughly tested as these drugs progressed through the full phase 3 trials and subsequent decades of daily use.

I know we all know this but it is spurious nonsense dressed up as realistic concerns, best ignored completely

I suspect that if the data from cohorts 1-6 is reasonably linear then there could be a temptation to extrapolate potential results for C7. I feel that even if the company refuse to do this then many will anyway.

Perhaps a heavily caveated 'expected results' could be published alongside the QC'd data.

Was thinking exactly the same WYN and sentiment that ties in with comments made at the AGM about not 'boosting' and ensuring all data is properly peer reviewed etc.

Totally support this approach and happy to wait longer if it means the data is fully QC'd

Now going for a lie down as I have just agreed with WYN and have come over all funny !!!

Ha ha exactly PL

I think that maxim could apply not only to Eggy but WYN and several others too

Better to keep your mouth shut and have people think you are a fool that open it and remove any doubt 🤣🤣🤣

Oncologist to Patient:

You’ve reached your MTD for doxorubicin, do you want;

A) To go into a palliative care program

B) Try this incredible new therapy that could not only extend your life but might put your cancer into remission, however it could create discomforting side-effects with your arthritis

C) Go on a course of Hollands meat and potato pies filled with potash.

I don't think it's helpful to keep referring to AVA6k & Pre/Cision as a drug. it isn't. It's a delivery system, it's a piece of chemistry that carries chemo to the tumour before being cleaved by FAPa .

It's a unique solution to a very old problem and in terms of valuation there are no precedents. It is not a new drug that can treat disease XYZ. It is a unique method of delivering potentially dozens of existing and new drugs directly to the place in the body where they are required.

Comparing Pre/Cision to anything that has gone before it is pointless, it is a unique and brilliant solution.

We know already, confirmed by the company via RNS, that the principle of this targeted delivery works, systemic toxicity is reduced and even if we see zero therapeutic benefits (we won't), then Pre/Cision will replace the current protocols of indiscriminate dosing because by reducing/removing side effects that in itself makes it a game changer.

It's is understandable that people compare Pre/Cision with other drug trials and other novel therapies and the associated risks but it isn't the same, it's completely unique and very soon the world outside of the company and a small network of private investors will realise this.

I would suggest that the BOD would choose to keep their 'optionality' open until the full publication of the data.

I feel we have enough experience in the boardroom who 'know what we have' and will understand that whatever our preference going forward, our position will be massively strengthened on the back of data that demonstrates a 'paradigm shift' in cancer treatment.

For what it is worth, I think a take over will be the end result for no other reason that there appears to be clear evidence that when BP sees a minnow with technology that they covet, they tend to gobble them up whole, usually for cash.